Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study
Subcutaneous guselkumab for both induction and maintenance was efficacious in treating participants with moderately to severely active Crohn's disease. Safety findings were consistent with those of guselkumab in approved indications, including ulcerative colitis. (ClinicalTrials.gov, Number: NCT05197049.).
Authors
- Chenglong Han (ORCID: https://orcid.org/0000-0001-7175-7834)
- Bruce E. Sands (ORCID: https://orcid.org/0000-0001-5762-5042)
- Ursula Elisabeth Seidler (ORCID: https://orcid.org/0000-0002-9600-2769)
- Ailsa Hart
- Tadakazu Hisamatsu (ORCID: https://orcid.org/0000-0002-1178-3536)
- Remo Panaccione
- Silvio Danese (ORCID: https://orcid.org/0000-0001-7341-1351)
- Geert D’Haens (ORCID: https://orcid.org/0000-0003-2784-4046)
- Mobolaji Olurinde
- Jewel Johanns
- Flávio Steinwurz (ORCID: https://orcid.org/0000-0003-1002-9766)
- Zijiang Yang (ORCID: https://orcid.org/0000-0001-6469-5217)
- Natalie A. Terry (ORCID: https://orcid.org/0000-0003-2570-6176)
- Yuhua Wang (ORCID: https://orcid.org/0000-0003-0161-1906)
- Qian Cao (ORCID: https://orcid.org/0000-0001-7938-7532)
- Aparna Sahoo
- Marion L. Vetter
- Jacqueline Yee
- Timothy E. Ritter
Institutions
- Johnson & Johnson (United States) (US)
- University of Calgary (CA)
- Kyorin University (JP)
- Hospital Israelita Albert Einstein (BR)
- Medizinische Hochschule Hannover (DE)
- IRCCS Ospedale San Raffaele (IT)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Gastroenterology
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1053/j.gastro.2025.02.033
- Citations
- 36
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 65.42
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Teva Pharmaceutical Industries
- Celgene
- Takeda Pharmaceutical Company
- Boston Scientific Corporation
- EA Pharma Co., Ltd.
- Mylan
- Kissei
- Celltrion
- Kyorin Pharmaceutical
- Mitsubishi Tanabe Pharma Corporation
- Genentech